Kontsioti, Elpida http://orcid.org/0000-0002-4053-0220
Maskell, Simon http://orcid.org/0000-0003-1917-2913
Dutta, Bhaskar
Pirmohamed, Munir http://orcid.org/0000-0002-7534-7266
Funding for this research was provided by:
RCUK | Engineering and Physical Sciences Research Council (EP/R51231X/1)
AstraZeneca
Article History
Received: 27 July 2021
Accepted: 13 January 2022
First Online: 4 March 2022
Change Date: 10 March 2022
Change Type: Update
Change Details: In this article the hyperlink provided for
Change Details: https://doi.org/10.6084/m9.figshare.c.5481408
Change Details: in reference 32 was incorrect. The original article has been corrected.
Competing interests
: EK receives PhD studentship that is jointly funded by AstraZeneca and the EPSRC. MP receives research funding from various organizations including the MRC and NIHR. He has also received partnership funding for the MRC Clinical Pharmacology Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly and Novartis) and grant funding from Vistagen Therapeutics. He has also unrestricted educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb and UCB. He has developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. He is part of the IMI Consortium ARDAT (ExternalRef removed). These funding sources were not utilized for this work. BD was AstraZeneca’s employee and shareholder when this article was submitted but has since ended his relationship with both.